Overview of the Deal
Shilpa Medicare Limited, a leading Indian pharmaceutical company listed on both BSE (530549) and NSE (SHILPAMED), has made a significant move to strengthen its global biosimilar footprint. Its wholly owned subsidiary, Shilpa Biologicals Private Limited (SBPL), has entered into a strategic licensing agreement with SteinCares to commercialize a biosimilar product across the Latin American market. This exclusive deal marks a pivotal milestone in Shilpa Medicare’s international expansion strategy and signals growing confidence in the affordability-driven biologics sector across emerging markets.
Who Are the Key Partners?
Shilpa Biologicals Private Limited
Shilpa Biologicals is a fully owned subsidiary of Shilpa Medicare Limited, headquartered in India. The company specializes in the development and manufacturing of high-quality, affordable biopharmaceuticals. Operating from its state-of-the-art biomanufacturing facility in Dharwad, Karnataka, Shilpa Biologicals has built a robust pipeline spanning biosimilars in immunology, oncology, and ophthalmology. The company is widely recognized for its adalimumab biosimilar, which has completed Phase III clinical trials and received marketing authorization in India, as well as international approvals in markets such as Morocco.
SteinCares
SteinCares is the commercial partner bringing Shilpa Biologicals’ biosimilar into the Latin American healthcare landscape. Under the newly signed agreement, SteinCares will hold exclusive rights to register, commercialize, and distribute the biosimilar product across the region, leveraging its established regulatory and distribution networks to accelerate market entry.
What Does the Agreement Cover?
The strategic licensing agreement between Shilpa Biologicals and SteinCares creates a clearly defined division of responsibilities designed to maximize efficiency and speed to market.
SteinCares’ Responsibilities
SteinCares will take on full ownership of the commercial path in Latin America. This includes managing regulatory registrations in individual countries across the region, building distribution infrastructure, and overseeing the commercialization of the biosimilar product at the market level.
Shilpa Biologicals’ Responsibilities
Shilpa Biologicals will focus on what it does best — science and manufacturing. The company will be responsible for completing the product development process and subsequently delivering long-term commercial manufacturing supply from its Dharwad facility in India. This ensures a consistent, high-quality supply chain supporting SteinCares’ market operations throughout Latin America.
Shilpa Biologicals’ Role in Manufacturing
The Dharwad manufacturing facility is a cornerstone of Shilpa Biologicals’ operational capabilities. Equipped for biologics development and commercial-scale production, the site supports everything from cell line development to GMP-compliant drug product manufacturing. It currently serves as the production base for multiple biosimilar and novel biologic programs, and will anchor the supply chain for this new Latin American venture. Shilpa Biologicals’ manufacturing expertise, combined with its commitment to affordability, makes it a compelling partner for companies looking to enter price-sensitive emerging markets.
Why Latin America Is a Strategic Biosimilar Market
Latin America represents one of the fastest-growing regions for biosimilar adoption. Several key factors are driving this trend. Healthcare systems across Brazil, Mexico, Argentina, Colombia, and other major economies are actively seeking cost-effective alternatives to expensive reference biologics to manage growing patient populations with chronic and autoimmune conditions. Regulatory frameworks in the region are also evolving, creating clearer pathways for biosimilar approvals. For Indian pharmaceutical companies like Shilpa Medicare, the region offers a compelling opportunity to scale affordable medicines globally while diversifying revenue streams away from saturated Western markets.
Shilpa Medicare’s Broader Biosimilar Pipeline
This Latin America deal is part of a wider and accelerating biosimilar strategy by Shilpa Biologicals. The company’s current pipeline includes an aflibercept biosimilar entering Phase III trials, an Fc fusion protein biosimilar, and another monoclonal antibody biosimilar in preclinical development. Beyond biosimilars, Shilpa Biologicals has also advanced a novel biological entity — recombinant human albumin — into Phase III clinical trials, with a commercial supply agreement already signed with Finland-based Orion Corporation for the European market. In early 2025, the company also signed a strategic development partnership with Switzerland-based mAbTree Biologics to co-develop a novel checkpoint inhibitor for immuno-oncological applications. Together, these initiatives paint the picture of a company rapidly maturing into a global biologics player.
Market Reaction and Investor Outlook
Despite the strategic significance of the deal, Shilpa Medicare’s stock fell 1.82% on the day of the announcement, reflecting broader market pressures rather than any negative sentiment toward the deal itself. Analyst attention is likely to remain focused on the timelines for product registration across Latin American countries, the commercial ramp-up by SteinCares, and Shilpa Biologicals’ manufacturing readiness for long-term supply. Given the company’s existing track record in biosimilar development and its growing international partnership portfolio, the deal is broadly viewed as a positive long-term move.
Conclusion
The exclusive biosimilar licensing agreement between Shilpa Biologicals and SteinCares marks a strategically significant expansion into one of the world’s most dynamic pharmaceutical growth regions. With Shilpa managing product development and manufacturing from India, and SteinCares driving commercialization across Latin America, the partnership is structured for operational efficiency and regional impact. As biosimilar demand continues to rise across emerging markets, this deal reinforces Shilpa Medicare’s position as a serious global contender in affordable biologics.
